Products
The YM BioSciences pipeline is hematology- and oncology-focused and aims to develop products for patients with cancer and cancer-related disorders. The investigational products in this pipeline are still in development. In some cases efficacy and safety have not yet been determined.
- Indication: Hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders
- JAK 1/2 small molecule inhibitor
- Ongoing Phase I/II and Phase II BID clinical studies in patients with myelofibrosis
-
Indication: Cancer
-
Monoclonal antibody
-
Ongoing Phase I, Phase II and Phase III clinical studies for lung cancer, pediatric and adult brain cancer, esophageal cancer, pancreatic cancer, prostate cancer, gastric cancer, cervical cancer, hepatic carcinoma and breast cancer
-
Approved for sale in certain countries
- Indication: Cancer
- Vascular Disrupting Agent (VDA)
- Ongoing Phase I/II clinical study
Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. CYT387 and CYT997 are wholly-owned by YM BioSciences Inc.